The latest phase of Tourism Australia’s global marketing campaign, There’s nothing like Australia, has been launched today in China – Australia’s fastest growing and most valuable overseas tourism market.
In addition to a new broadcast ad and print executions the campaign boasts a strong digital and social media focus, and will leverage the advocacy of Tourism Australia’s three million Facebook fans. Other elements include a new, interactive tablet app and hub on www.australia.com, to take customers further into the stories played out in the ad and provide more information on the locations.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56340-tourism-australia-global-marketing-campaign-there-s-nothing-like-australia
At an ever-increasing rate, CEOs and business executives are relying on their peers, particularly outside their own expertise, to help them grow personally, professionally and organizationally. Yet, many of today’s business leaders have unpredictable travel schedules, live in outlying markets, or simply prefer to connect with their peers online. To meet the needs of these executives, Vistage International, the world’s foremost peer advisory membership organization for business leaders, has launched a new program – a robust online, issue-resolution offering that makes it possible to engage a group of business peers on specific subjects. Vistage Connect provides executives with access to the professionally facilitated “advisory board” they need to process and solve their toughest business challenges and optimize their opportunities. The new online platform has been in the research and test phase for the past year and is now officially available to CEOs and business executives of growing and mature companies.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/vistage/51158/
On May 26, 2012, the 22 teams competing for the Solar Decathlon China 2013 made a group appearance to the public in the City of Datong, Shanxi Province, marking the successful close to the team selection process and the official start of the promotion phase.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56423-solar-decathlon-china-2013
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Fluke Corporation, the global leader in portable electronic test and measurement technology, announces the availability of the Fluke® 430 Series II Three Phase Power Analyzers, the first tools to use a patented algorithm to measure energy wasted by power quality issues and quantify its cost. By providing the ROI data needed to justify power quality improvements, the 430 Series II helps facilities reduce electrical power consumption and improve the performance and lifespan of electro-mechanical equipment.
To view Multimedia News Release, go to MNR http://www.multivu.com/mnr/54283-fluke-435-three-phase-power-quality-analyzer-test-generators-motors
Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are launching the first FDA-approved, Phase I safety study on the use of cord blood stem cells to treat children with sensorineural hearing loss.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53686-cord-blood-childrens-memorial-hermann-fda-approved-stem-cells-hearing-loss
The Ad Council, in partnership with the U.S. Department of the Treasury and the U.S. Department of Housing and Urban Development (HUD), have joined together to launch a new phase of their Foreclosure Prevention Assistance Public Service Advertising (PSA) Campaign. The campaign aims to increase awareness of the Making Home Affordable® Program’s free resources and assistance for homeowners who are struggling with their mortgage payments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51783-ad-council-making-home-affordable-english-psa
National Instruments (Nasdaq: NATI) today introduced a 14 GHz version of its NI PXIe-5665 high-performance RF vector signal analyzer (VSA), which delivers best-in-class dynamic range and accuracy in a cost-effective PXI form factor. The new VSA features industry-leading phase noise and dynamic range, regardless of form factor, including traditional rack-and-stack instruments. Because of its PXI platform, the VSA can deliver measurement speeds up to 20 times faster than box instruments and for less cost. Additionally, it takes advantage of multicore computing architectures and parallel programming capabilities through NI LabVIEW system design software. It also offers peer-to-peer data streaming for signal processing and a flexible multiple input, multiple output (MIMO) architecture for phase-coherent measurements. Such features make it ideal for demanding RF test applications including radio detection and ranging (RADAR), satellite, radio and harmonic testing.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nationalinstruments/51200/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Baha Mar celebrated the commencement of construction with its official groundbreaking ceremony on Feb. 21, 2011. The largest single-phase resort development in the history of the Caribbean, the 1,000-acre, $3.4 billion resort, gaming and entertainment complex is slated to open in late 2014, and will include some of the world’s most famous hotel brands, setting a new standard of luxury for the hospitality industry.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bahamar/48767/
The University of Texas Health Science Center at Houston (UTHealth) has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child’s own umbilical cord blood stem cells for traumatic brain injury in children. The study is being performed in conjunction with Children’s Memorial Hermann Hospital, UTHealth’s primary children’s teaching hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cordblood/48021/
